CP143756471 | Newsroom Ready: Merck announces Molnupiravir manufacturing in Canada for COVID-19

CP17178065 | Canada's $850M promise for international COVID-19 fight 'only a beginning'

CP141789821 | Health Canada approves first COVID-19 vaccine for kids aged five to 11

CP160599428 | Health Canada approves first COVID-19 vaccine for children under five

CP115594721 | Ford appeals to Biden for COVID-19 vaccines

CP19569371 | Canada buys options for fifth potential COVID-19 vaccine

CP142139971 | Plane carrying COVID-19 vaccines for kids touches down in Canada

CP114035121 | 'We are headed in a good direction:' Manitoba announces 133 new COVID-19 cases

CP111820571 | National plans for COVID-19 vaccine distribution in the works: Hajdu

CP115080514 | Ford defends COVID-19 stay-at-home order

Placeline/People

City Vaughan

Country Canada

Merck announces Molnupiravir manufacturing in Canada for COVID-19

Merck has announced a partnership with Thermo Fisher Scientific to manufacture Molnupiravir, an oral antiviral medicine for the treatment of COVID-19, in Whitby, Ont. The companies will manufacture Molnupiravir for distribution in Canada and the U.K., as well as markets in Europe, Asia and Latin America, pending local market approvals.

Source name:

Unique identifier: CP143754121

Legacy Identifier: n_COVID-Treatment20211206T1330

Type: Video

Duration: 2m46s

Dimensions: 1920px × 1080px 196.41 MB

Usage rights: FOR ONE TIME USE ONLY. NO STORAGE FOR FUTURE USE.

Create Date: 12/6/2021 1:30:00 PM

Display aspect ratio: 16:9